Biotech startups in Cambridge, United Kingdom
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| bit.bio | Cambridge | Series D | $25.0M | 2026-11-04 |
| T-Therapeutics | Cambridge | Series B | $133.0M | 2026-11-05 |
| Microbiotica | Cambridge | Series C | $47.9M | 2026-10-16 |
| Sparxell | Cambridge | Seed | $5.0M | 2026-02-03 |
| CellCentric | Cambridge | Series D | $220.0M | 2026-05-06 |
| Nuclera | Cambridge | Series C | $12.0M | 2026-01-13 |
| Lucida Medical | Cambridge | Series A | $11.5M | 2026-03-30 |
| Cyted | Cambridge | Series B | $44.0M | 2025-08-30 |
8 rows of the CSV in 5 of its 18 columns.
- The 85 biotech startups in Cambridge, United Kingdom have raised $3.0B in total.
- 16 of them closed their most recent round in the last 12 months, $748.2M combined.
- The largest of those rounds is CellCentric's $220.0M Series D, dated May 2026.
- The most recent is T-Therapeutics' $133.0M Series B on 5 November 2026.
- Innovate UK is an investor in 7 of them, more than any other fund.
- Health care is the most common other sector, with 66 companies (78%).
- 26% were founded in 2020 or later; the median founding year is 2016.
- The most common team size is 11 to 50 employees (49% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
13 of 85| Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|
| T-Therapeutics | T-Therapeutics develops T cell receptor therapies, spun off from the University of Cambridge. | Biotech | Series B | $133.0M | 2026-11-05 | $224.6M | F-Prime, Sofinnova Partners, Digitalis Ventures +2 | 51 to 100 | 2022 |
| bit.bio | Bit.bio provides engineered human cell products and platform services for biomedical research and drug discovery. | Biotech | Series D | $25.0M | 2026-11-04 | $250.0M | Metaplanet, Foresite Capital | 101 to 250 | 2016 |
| Microbiotica | Microbiotica develops live bacterial microbiome therapeutics and associated biomarkers. | Biotech | Series C | $47.9M | 2026-10-16 | $130.7M | Seventure Partners, IP Group, Cambridge Innovation Capital +1 | 11 to 50 | 2016 |
| CellCentric | CellCentric develops small molecule therapies for treating cancer and multiple myeloma. | Biotech | Series D | $220.0M | 2026-05-06 | $475.7M | Innovate UK, 5Y Capital, RA Capital Management +2 | 11 to 50 | 2003 |
| Lucida Medical | Lucida Medical develops software for cancer diagnosis using MRI and radiology imaging, particularly for prostate cancer. | Biotech | Series A | $11.5M | 2026-03-30 | $22.5M | Innovate UK, XTX Ventures, WDH Investments | 11 to 50 | 2019 |
| Sparxell | Sparxell creates new colors and effects. | Biotech | Seed | $5.0M | 2026-02-03 | $10.2M | Katapult, Joyance Partners, Earth Venture Capital +1 | 11 to 50 | 2022 |
| Nuclera | Nuclera provides a protein prototyping system that makes proteins readily available to drug discovery researchers. | Biotech | Series C | $12.0M | 2026-01-13 | $157.8M | Innovate UK, Verve Ventures, Amadeus Capital Partners +2 | 101 to 250 | 2013 |
| Cyted | Cyted uses AI and digital pathology to improve the detection and diagnosis of diseases, including cancer. | Artificial intelligence | Series B | $44.0M | 2025-08-30 | $83.4M | Innovate UK, MedTech Innovator, Morningside +1 | 51 to 100 | 2018 |
| Shift Bioscience | Shift Bioscience discovers drug targets for age-linked diseases using simulation. | Artificial intelligence | Seed | $16.3M | 2024-10-15 | Healthspan Capital | 11 to 50 | 2017 | |
| CardiaTec Biosciences | CardiaTec Biosciences combines AI and expert talent to redesign cardiovascular drug discovery. | Artificial intelligence | Seed | $6.5M | 2024-09-10 | APEX Ventures, Montage Ventures, Continuum Health Ventures +1 | 11 to 50 | 2021 | |
| Zetta Genomics | Zetta Genomics manages large-scale genomic data for precision medicine. | Biotech | Seed | $2.3M | 2024-02-08 | $8.0M | Nina Capital, APEX Ventures, University of Cambridge Enterprise +1 | 11 to 50 | 2018 |
| Apollo Therapeutics | Apollo Therapeutics develops medicines by translating medical research into biopharmaceutical portfolios. | Biotech | Series C | $33.5M | 2024-01-02 | $397.9M | UCL Technology Fund, Patient Square Capital, Rock Springs Capital | 51 to 100 | 2016 |
| Mogrify | Mogrify develops in vivo reprogramming therapies for patients with degenerative diseases. | Biotech | Series A | $10.0M | 2023-10-02 | Parkwalk Advisors, 24 Haymarket, Ahren Innovation Capital | 11 to 50 | 2019 |
Table 1. Biotech startups in Cambridge, United Kingdom: the 13 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 85.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | CellCentric | CellCentric develops small molecule therapies for treating cancer and multiple myeloma. | Biotech | Series D | $220.0M | 2026-05-06 | $475.7M | Innovate UK, 5Y Capital, RA Capital Management +2 | 11 to 50 | 2003 |
| 2 | T-Therapeutics | T-Therapeutics develops T cell receptor therapies, spun off from the University of Cambridge. | Biotech | Series B | $133.0M | 2026-11-05 | $224.6M | F-Prime, Sofinnova Partners, Digitalis Ventures +2 | 51 to 100 | 2022 |
| 3 | Microbiotica | Microbiotica develops live bacterial microbiome therapeutics and associated biomarkers. | Biotech | Series C | $47.9M | 2026-10-16 | $130.7M | Seventure Partners, IP Group, Cambridge Innovation Capital +1 | 11 to 50 | 2016 |
| 4 | bit.bio | Bit.bio provides engineered human cell products and platform services for biomedical research and drug discovery. | Biotech | Series D | $25.0M | 2026-11-04 | $250.0M | Metaplanet, Foresite Capital | 101 to 250 | 2016 |
| 5 | Nuclera | Nuclera provides a protein prototyping system that makes proteins readily available to drug discovery researchers. | Biotech | Series C | $12.0M | 2026-01-13 | $157.8M | Innovate UK, Verve Ventures, Amadeus Capital Partners +2 | 101 to 250 | 2013 |
| 6 | Lucida Medical | Lucida Medical develops software for cancer diagnosis using MRI and radiology imaging, particularly for prostate cancer. | Biotech | Series A | $11.5M | 2026-03-30 | $22.5M | Innovate UK, XTX Ventures, WDH Investments | 11 to 50 | 2019 |
| 7 | Sparxell | Sparxell creates new colors and effects. | Biotech | Seed | $5.0M | 2026-02-03 | $10.2M | Katapult, Joyance Partners, Earth Venture Capital +1 | 11 to 50 | 2022 |
Table 2. Biotech startups in Cambridge, United Kingdom: the 7 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Innovate UK | Entrepreneurship program | Swindon, United Kingdom | 7 | 8% | 3 | CellCentric, Lucida Medical, Nuclera |
| 2 | University of Cambridge Enterprise | University program | Cambridge, United Kingdom | 2 | 2% | 1 | T-Therapeutics |
| 3 | Cambridge Innovation Capital | Venture capital firm | Cambridge, United Kingdom | 2 | 2% | 2 | T-Therapeutics, Microbiotica |
| 4 | Future Planet Capital | Venture capital firm | London, United Kingdom | 2 | 2% | 2 | CellCentric, Nuclera |
| 5 | O2h Ventures | Venture capital firm | Hauxton, United Kingdom | 2 | 2% | ||
| 6 | APEX Ventures | Venture capital firm | Vienna, Austria | 2 | 2% | ||
| 7 | Foresite Capital | Private equity firm | San Francisco, United States | 1 | 1% | 1 | bit.bio |
| 8 | Metaplanet | Venture capital firm | Tallinn, Estonia | 1 | 1% | 1 | bit.bio |
| 9 | Sofinnova Partners | Venture capital firm | Paris, France | 1 | 1% | 1 | T-Therapeutics |
| 10 | Digitalis Ventures | Venture capital firm | New York, United States | 1 | 1% | 1 | T-Therapeutics |
| 11 | F-Prime | Venture capital firm | Cambridge, United States | 1 | 1% | 1 | T-Therapeutics |
| 12 | British Patient Capital | Venture capital firm | Sheffield, United Kingdom | 1 | 1% | 1 | Microbiotica |
| 13 | Seventure Partners | Venture capital firm | Paris, France | 1 | 1% | 1 | Microbiotica |
| 14 | IP Group | Venture capital firm | London, United Kingdom | 1 | 1% | 1 | Microbiotica |
| 15 | Joyance Partners | Venture capital firm | San Francisco, United States | 1 | 1% | 1 | Sparxell |
Table 3. Biotech startups in Cambridge, United Kingdom: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 66 | 78% | $2.8B |
| Software | 13 | 15% | $140.5M |
| Artificial intelligence | 9 | 11% | $118.0M |
| Hardware | 3 | 4% | $14.7M |
| Energy | 1 | 1% | $2.8M |
| Education | 1 | 1% |
Table 4. Biotech startups in Cambridge, United Kingdom by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Pre-seed | 9 | 11% | $1.6M |
| Seed | 29 | 34% | $5.3M |
| Series A | 19 | 22% | $11.0M |
| Series B | 15 | 18% | $23.9M |
| Series C | 8 | 9% | $31.0M |
| Series D+ | 5 | 6% | $88.0M |
Table 5. Biotech startups in Cambridge, United Kingdom by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 2 | 12% | $158.0M |
| October 2026 | 2 | 12% | $50.7M |
| September 2026 | 2 | 12% | $1.1M |
| July 2026 | 1 | 6% | $14.7M |
| May 2026 | 2 | 12% | $221.6M |
| April 2026 | 1 | 6% | $56.0M |
| March 2026 | 2 | 12% | $98.6M |
| February 2026 | 2 | 12% | $20.5M |
| January 2026 | 1 | 6% | $12.0M |
| November 2025 | 1 | 6% | $115.0M |
Table 6. Biotech startups in Cambridge, United Kingdom: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 15 | 18% | $633.2M |
| 2025 | 9 | 11% | $276.8M |
| 2024 | 13 | 15% | $134.2M |
| 2023 | 8 | 9% | $55.5M |
| 2022 | 5 | 6% | $11.8M |
| 2021 | 6 | 7% | $206.1M |
Table 7. Biotech startups in Cambridge, United Kingdom by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 7 | 8% |
| 2020 to 2022 | 15 | 18% |
| 2015 to 2019 | 38 | 45% |
| 2010 to 2014 | 17 | 20% |
| Before 2010 | 8 | 9% |
Table 8. Biotech startups in Cambridge, United Kingdom by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 32 | 38% |
| 11 to 50 | 41 | 49% |
| 51 to 100 | 9 | 11% |
| 101 to 250 | 2 | 2% |
Table 9. Biotech startups in Cambridge, United Kingdom by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its headquarters is in Cambridge, United Kingdom. On 16 November 2026 that is 85 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 13 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 85 rows: 13 have no round amount, 0 no city and 29 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Cambridge, United Kingdom are on the list?
- 85, in the file dated 16 November 2026. 16 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 85 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.